KRAS and colorectal carcinoma: MiR-4689 inhibits the activation of RAF/MEK/MAPK, RAF/MEK/ERK and PI3K/AKT pathways by targeting KRAS and AKT1 [120], suggesting that miR-4689 provides a new possibility for targeted therapy of refractory KRAS mutant CRC.